Skip to main content
. 2022 Mar 16;79(17):1717–1756. doi: 10.1016/j.jacc.2022.02.003
Committee Member Employment Consultant Speakers Bureau Ownership/ Partnership/ Principal Personal Research Institutional, Organizational, or Other Financial Benefit Expert Witness
Ty J. Gluckman (Co-Chair) Providence Heart Institute
Providence St. Joseph Health—Medical Director, Center for Cardiovascular Analytics, Research, and Data Science (CARDS)
None None None None None None
Nicole M. Bhave (Co-Chair) University of Michigan Medical School—Associate Professor of Medicine
Cardiovascular Medicine
None None None None None None
Larry A. Allen (Vice Chair) University of Colorado School of Medicine—Professor of Medicine;
Kenneth Poirier Chair;
Associate Head for Clinical Affairs, Cardiology
Medical Director, Advanced Heart Failure
  • Abbott Laboratories

  • Amgen Inc.

  • Novartis Corporation

None None None None None
Eugene H. Chung (Vice Chair) University of Michigan Medical School—Professor of Medicine; Director, Sports Cardiology Clinic None None None None None None
Erica S. Spatz (Vice Chair) Yale University School of Medicine—Associate Professor, Section of Cardiovascular Medicine; Director, Preventive Cardiovascular Health Program None None None None None None
Enrico Ammirati Niguarda Hospital, Milan, Italy—Cardiologist, Advanced Heart Failure, LVAD and Cardiac Transplant None None None None
  • Myocarditis Foundation

None
Aaron L. Baggish Massachusetts General Hospital—Cardiovascular Performance Program Director None None None None None None
Biykem Bozkurt Baylor College of Medicine—The Mary and Gordon Cain Chair and Professor of Medicine; Associate Provost of Faculty Affairs; Senior Associate Dean of Faculty Development; Director, Winters Center for Heart Failure Research; Associate Director, Cardiovascular Research Institute; Vice-Chair of Medicine
  • Amgen

None None None
  • Abbott Laboratories

None
William K. Cornwell, III University of Colorado Anschutz Medical Campus—Cardiologist, Advanced Heart Failure, LVAD and Cardiac Transplant None None None None None None
Kimberly G. Harmon University of Washington—Team Physician None None None None None None
Jonathan H. Kim Emory Clinical Cardiovascular Research Institute, Emory School of Medicine—Associate Professor of Medicine, Director of Sports Cardiology None None None None None None
Anuradha Lala Icahn School of Medicine at Mount Sinai—Associate Professor, Cardiology & Population Health Science; Program Director, Advanced Heart Failure & Transplant Fellowship None None None None None None
Benjamin D. Levine Institute for Exercise & Environmental Medicine—Director; Texas Health Presbyterian Dallas—Chair for Wellness and Chair for Cardiovascular Research; The University of Texas Southwestern Medical Center—Professor of Medicine and Cardiology None None
  • Amgen Inc

None None None
Matthew M. Martinez Morristown Medical Center—Director Sports Cardiology and Hypertrophic Cardiomyopathy Center
  • Bristol Myers Squibb

None None None None None
Oyere Onuma Yale University School of Medicine— Assistant Professor of Cardiology None None None None None None
Dermot Phelan Sanger Heart and Vascular Institute, Atrium Health—Director of Sports Cardiology
  • Bristol Myers Squibb

None None None None None
Valentina O. Puntmann University Hospital Frankfurt—Associate Professor, Consultant Cardiologist (Cardiovascular Magnetic Resonance Imaging)
  • Bayer AG

  • CMR International

None None None None None
Saurabh Rajpal The Ohio State University Wexner Medical Center—Assistant Professor None None None None None None
Pam R. Taub University of California San Diego Medical Center—Professor of Medicine; Director of Step Family Foundation Cardiovascular Rehabilitation and Wellness Center
  • Amgen

None None None None None
Amanda K. Verma Washington University School of Medicine—Assistant Professor of Medicine, Advanced Heart Failure and Transplant Cardiology; Director of COVID Cardiology Clinics None None None None None None

This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development process. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity or ownership of ≥$5,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted.

According to the ACC, a person has a relevant relationship IF: a) the relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the document; b) the company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the document or makes a competing drug or device addressed in the document; or c) the person or a member of the person’s household, has a reasonable potential for financial, professional or other personal gain or loss as a result of the issues/content addressed in the document.

ACC = American College of Cardiology; LVAD = left ventricular assist device.

Significant relationship.